FIG 1.
Mean (±SD) plasma concentration-versus-time profiles of levonadifloxacin before and in the 12-h interval following the first (A) and ninth (B) oral doses of alalevonadifloxacin (1,000 mg every 12 h).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.